Park Ha Biological Technology (BYAH) Current Deferred Revenue (2023 - 2026)
Park Ha Biological Technology (BYAH) posted quarterly Current Deferred Revenue of $194968.0 for Q2 2026, little changed quarter-over-quarter from $194753.0 in Q4 2025.
Park Ha Biological Technology (BYAH) Current Deferred Revenue (2023 - 2026) Analysis & Trends
Park Ha Biological Technology's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $194968.0 for Q2 2026.
- In Q2 2026, Current Deferred Revenue changed N/A year-over-year to $194968.0; the TTM figure through Apr 2026 stood at $194968.0 (changed N/A YoY), while the FY2025 annual figure was $194753.0, changed N/A from the prior year.
- Current Deferred Revenue for Q2 2026 stood at $194968.0, roughly flat from $194753.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $250549.0 in Q4 2023, with the low at $194753.0 in Q4 2025.
- The 3-year median for Current Deferred Revenue is $194968.0 (2026), against an average of $213423.3.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Procter & Gamble | 334.68 Bn | 324.73 Bn | 10.28 Bn |
| 2 | Unilever | 135.06 Bn | 122.54 Bn | - |
| 3 | Colgate Palmolive | 73.11 Bn | 71.74 Bn | 3.30 Bn |
| 4 | Kenvue | 36.14 Bn | 35.03 Bn | 2.30 Bn |
| 5 | Kimberly Clark | 35.84 Bn | 34.89 Bn | 1.60 Bn |
| 6 | Estee Lauder Companies | 30.63 Bn | 27.51 Bn | 2.84 Bn |
| 7 | Church & Dwight | 23.49 Bn | 23.23 Bn | 693.90 Mn |
| 8 | Clorox | 12.90 Bn | 12.75 Bn | 804.00 Mn |
| 9 | Yatsen Holding | 5.79 Bn | 5.65 Bn | 153.20 Mn |
| 10 | Park Ha Biological Technology | 1.04 Mn | -4.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 194,968.00 |
| Oct 31, 2025 | 194,753.00 |
| Oct 31, 2023 | 250,549.00 |